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To validate the provisional findings of a number of smaller studies and explore additional determinants of
characteristic diagnostic investigation results across the entire clinical spectrum of sporadic Creutzfeldt–Jakob
disease (CJD), an international collaborative study was undertaken comprising 2451 pathologically confirmed
(definite) patients.We assessed the influence of age at disease onset, illness duration, prion protein gene (PRNP)
codon 129 polymorphism (either methionine or valine) and molecular sub-type on the diagnostic sensitivity of
EEG, cerebral MRI and the CSF 14-3-3 immunoassay. For EEG and CSF 14-3-3 protein detection, we also
assessed the influence of the time point in a patient’s illness at which the investigation was performed on the
likelihood of a typical or positive result. Analysis included a large subset of patients (n = 743) in whommolecular
sub-typing had been performed using a combination of the PRNP codon 129 polymorphism and the form of
protease resistant prion protein [type 1 or 2 according to Parchi et al. (Parchi P, Giese A, Capellari S, Brown P,
Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N,
Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H. Classification of sporadic Creutzfeldt–Jakob disease
based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224–233.)] present in the
brain. Findings for the whole group paralleled the subset withmolecular sub-typing data available, showing that
age at disease onset and disease duration were independent determinants of typical changes on EEG, while
illness duration significantly influenced positive CSF 14-3-3 protein detection; changes on brain MRI were not
influenced by either of these clinical parameters, but overall, imaging data were less complete and consequently
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conclusions are more tentative. In addition to age at disease onset and illness duration, molecular sub-type was
re-affirmed as an important independent determinant of investigation results. In multivariate analyses that
includedmolecular sub-type, time point of the investigation during a patient’s illness was found not to influence
the occurrence of a typical or positive EEG or CSF 14-3-3 protein result. A typical EEG was most often seen in
MM1 patients and was significantly less likely in the MV1, MV2 and VV2 sub-types, whereas VV2 patients had an
increased likelihood of a typical brain MRI. Overall, the CSF 14-3-3 immunoassay was the most frequently
positive investigation (88.1%) but performed significantly less well in the very uncommon MV2 and MM2 sub-
types. Our findings confirm a number of determinants of principal investigation results in sporadic CJD and
underscore the importance of recognizing these pre-test limitations before accepting the diagnosis excluded or
confirmed. Combinations of investigations offer the best chance of detection, especially for the less common
molecular sub-types such as MV2 and MM2.
Keywords: sporadic CJD; diagnostic investigation results; molecular sub-typing
Abbreviations: CJD = Creutzfeldt–Jakob disease; PrPres = protease-resistant prion protein; PSWC = periodic sharp
wave complexes
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Introduction
Pre-mortem diagnosis of the rare, transmissible neurodegen-
erative disorder, sporadic Creutzfeldt–Jakob disease (CJD),
largely relies on an appropriate clinical profile supported by
characteristic findings on routine investigations such as the
EEG and CSF analysis (Collins et al., 2004). Neuropatholo-
gical examination of the brain remains necessary to achieve a
definite diagnosis. Cerebral MRI may also demonstrate
highly suggestive changes and is assuming a greater role
in CJD evaluation but is not currently included in diagnostic
criteria for surveillance purposes (Collie et al., 2001;
Meissner et al., 2004; Shiga et al., 2004; Tschampa et al.,
2005). Although the diagnostic utility of these investigations
(particularly the EEG and CSF 14-3-3 protein detection) has
been supported by a number of studies (Steinhoff et al.,
1996, 2004; Zerr et al., 2000a), they remain imperfect sur-
rogate markers, with apparent non-uniform sensitivity across
the clinical spectrum of sporadic CJD (Parchi et al., 1999).
Different clinical and pathological sub-types of sporadic
CJD have been linked to polymorphism status at codon 129
of PRNP combined with the type (1 or 2) of protease-
resistant prion protein (PrPres) found in the brain, and
together these probably define different human prion strains
(Parchi et al., 1999; Hill et al., 2003; Korth et al., 2003). The
most widely used scheme distinguishes only two PrPres types
(Parchi et al., 1999), while another commonly employed
nomenclature delineates a greater number (Hill et al.,
2003). Employing this nosology to sub-type sporadic CJD,
the EEG has been shown to vary widely between the specific
molecular sub-types in demonstrating characteristic or typi-
cal changes (Parchi et al., 1999; Zerr et al., 2000b). Generally,
the likelihood of characteristic changes on the EEG was
reported to be highest in MM homozygotes, reduced in
heterozygotes and lowest in VV carriers. Immunoassay for
14-3-3 proteins in CSF, increasingly utilized in the diagnostic
evaluation of patients with suspect CJD (Zerr et al., 2000a),
has also been shown to vary in rates of positivity according to
molecular sub-type, with the likelihood of noticeably
reduced detection rates in heterozygous patients with type
2 PrPres (MV2) (Zerr et al., 2000b; Otto et al., 2002;
Castellani et al., 2004). A notable difficulty with all previous
reports assessing rates of positive diagnostic investigations in
molecular sub-types of sporadic CJD is the small numbers of
patients studied, especially the less common phenotypic sub-
types. Such small patient numbers militate against the relia-
bility of the observations and have precluded multivariate
analyses to assess for covariates and probable confounding
factors. A corollary, unexplored so far, is whether within each
of the molecular subgroups and across the phenotypic spec-
trum of sporadic CJD there are additional independent vari-
ables influencing diagnostic test results. Consequently, there
remains a need to more confidently establish the diagnostic
utility of these investigations across the various molecular
sub-types of sporadic CJD and define further determinants
of their sensitivity and specificity across the entire clinical
range. More clearly defining additional factors influencing
the sensitivity and specificity of these principal investigations
has important practical implications when investigating indi-
vidual patients.
As part of a collaborative multi-national CJD surveillance
program (EUROCJD) initiated in 1993, we assessed the effect
of patient clinical features such as age at onset, illness dura-
tion and PRNP codon 129 polymorphism on the diagnostic
sensitivity of EEG, CSF 14-3-3 immunoassay and cerebral
MRI in a large, population-based sample of 2451 patholo-
gically confirmed (definite) sporadic cases of CJD, employ-
ing harmonized case definitions and data sets. Further,
similar analysis was undertaken in a subset of patients
(n = 743) in whom molecular sub-typing using brain PrPres
isotype and codon 129 polymorphism had been determined.
Inclusion of this data allowed detailed assessment of the
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variation in positive test results across the molecular sub-
types, as well as whether patient parameters such as age at
onset, illness duration and the specific time point at which
the investigation was performed during a patient’s illness
were additional independent determinants of investigation
results.
Patients and methods
The present study was undertaken as part of the ongoing activities
of the prospective CJD surveillance programme (EUROCJD) con-
ducted by the European Union and allied countries. In 1993,
national surveillance registers commenced in France, Germany,
Italy, The Netherlands, Slovakia and the UK, with the aim of
ascertaining all patients diagnosed with probable or definite CJD
in the respective countries. The study was extended in 1997 and
again in 1998 to include Australia, Austria, Canada, Spain and
Switzerland. EUROCJD collaborative study methods utilizing
standardized case definitions and centralized harmonized demo-
graphic data sets were as described previously (Pocchiari et al.,
2004; Ladogana et al., 2005a).
The study comprised all patients (n = 2451) with definite spora-
dic CJD who died between 31 December 1992 and 31 December
2002: 136 cases from Australia, 68 from Austria, 146 from Canada,
491 from France, 450 from Germany, 342 from Italy, 100 from The
Netherlands, 438 from the UK, 18 from Slovakia, 183 from Spain
and 79 from Switzerland. A diagnosis of definite sporadic CJD
required neuropathological confirmation most commonly through
post-mortem but occasionally through brain biopsy. Analysis of the
PRNP open reading frame was performed in the majority of patients
to exclude genetic CJD, as clinical differentiation from sporadic CJD
is not always possible (Collins et al., 2000; Ladogana et al., 2005b).
Of the 2451 patients, 746 had their brain PrPres isotype determined,
which in combination with PRNP codon 129 genotyping allowed
molecular sub-typing according to the system of Parchi et al.,
(1999). Whenever possible, PrPres typing was based on analysis
of a number of brain regions, including cerebral cortex, striatum
or thalamus and cerebellum, although the preferred number and
precise location of sampling sites varied between participating
countries.
Whenever possible, all EEGs and MRI brain scans were reviewed
by a member of the surveillance system and scored for the presence
or absence of typical or characteristic diagnostic features. EEG
records were scored positive or characteristic when they fulfilled
validated criteria (Steinhoff et al., 2004): sustained periodic sharp
wave complexes (PSWC) with a variability of <500 ms, with the
periodic complexes (lasting 100–600 ms) demonstrating a bi- or tri-
phasic morphology and seen in a generalized or lateralized distri-
bution. The CSF 14-3-3 immunoassays were performed in each of
the national surveillance centres using western blotting, with con-
formity of testing methods and results interpretation confirmed by
blinded sample exchange programme. On cerebral MRI, high signal
in the putamen and caudate nucleus when using long-repetition
time pulse sequences was considered a positive finding for sporadic
CJD (Collie et al., 2001); however, there was no systematic use of
particular techniques such as fluid attenuated inversion recovery
(FLAIR) or diffusion weighted imaging (DWI).
For assessment of the influence of the timing of the investigation
during a patient’s illness on the test result, data sets were of suffi-
cient size for EEG and CSF 14-3-3 protein detection to allow this
type of analysis. Acknowledging that the median total illness
duration was 5 months, we chose to divide each patient’s sympto-
matic phase into thirds (first, middle and final) rather than into a
greater number of epochs. This was to ensure avoiding the creation
of illness periods of such brevity, especially at the onset of symp-
toms, that they would be unlikely to correspond to a clinically
meaningful phase of a patient’s illness during which investigations
would usually be undertaken, and if undertaken because of the
development of symptoms suggesting neurological dysfunction,
that these features were sufficiently developed that the investigations
had a reasonable likelihood of displaying abnormalities. The median
times (range in months) from the onset of symptoms for the ana-
lyses of each of the first, middle and final thirds of patient’s illnesses
for assessing CSF 14-3-3 protein detection were 1 (0–10), 2.5 (1–17)
and 4 months (1–41), respectively. With respect to EEG findings,
the median times (range in months) from the onset of symptoms
for the analyses of each of the first, middle and final thirds of
patient’s illnesses were 1 (0–18), 2 (1–42) and 4 months (1–41),
respectively.
All data were centralized and analysed collaboratively.
Statistical analysis
Descriptive statistics were calculated for the whole sample and for
every molecular sub-type of the disease. Fisher’s exact and Mann–
Whitney tests were used to assess differences between qualitative
and quantitative variables, respectively. The number of positive
findings (acknowledging that patients may have undergone multiple
tests) over the total number of tested CJD cases for EEG, MRI and
the CSF 14-3-3 immunoassay was determined for each stratum. The
frequency of positive results (number of positive test results in total
number of patients) was then calculated for EEG, MRI and the CSF
14-3-3 test for each stratum.
In order to analyse the independent effect of each factor on
positive test results, taking into account possible confounders, we
fitted two multiple logistic regression models with the test result as
output. Both models included age at onset, and disease duration as
predictors, and included country of origin, year of death and gender
as covariates.
In the first model PRNP codon 129 genotype was entered as a
predictor, while in the second model we used the molecular sub-
type (combination of PRNP codon 129 genotype and PrPres type).
Age at onset was categorized into clinically meaningful groups, with
patients younger than 50 years serving as the reference group.
Disease duration was also categorized with the same criteria into
three groups: duration <6, 6–12 and >12 months. PRNP codon 129
genotype was entered in the model using two dummy variables,
with MM as the reference group; for molecular sub-types we created
eight dummy variables (MM2, MM1/2, MV1, MV2, MV1/2, VV1,
VV2 and VV1/2) with MM1 group as reference. Adjusted odd ratios
(ORs) and 95% confidence intervals (CIs) were generated. All sta-
tistical analyses were performed using SPSS 11.0 for Windows 2000
(SPSS Inc., Chicago, IL).
Results
Table 1 summarizes the salient features of all definite spora-
dic CJD cases. Of the 2451 patients identified, 1329 were
females (54.2%). The median age at death was 68 years
(range: 20–95), while the median disease duration was
5 months (range: 1–81).
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An EEG was performed on 2083 patients (85%). Of
those undergoing EEG, 1216 cases showed typical
PSWCs (58.4%) (Table 1). The codon 129 genotype had a
significant effect on the likelihood of a positive result of the
EEG in sporadic CJD patients (Table 2), which ranged from
73.2% in MM homozygotes to 21.5% in VV homozygotes.
After adjusting for possible confounding variables
(country, sex, year of death, age at onset and disease
duration), the prevalence of PSWC on the EEG was
significantly decreased in heterozygotes (P < 0.001) and
VV homozygotes (P < 0.001). The median age of death of
sporadic CJD patients with a typical EEG was 69.0 (range:
34–92) versus 66 years (range: 20–88) in patients with an
atypical EEG (P < 0.001). The presence of PSWC was
further analysed by age at onset and disease duration
(Table 3). The likelihood of a typical EEG steadily increased
with age (P < 0.001, adjusted for the same variables),
while there was an inverse correlation with disease duration
(P = 0.001).
CSF 14-3-3 protein analysis was performed on 1521 cases
(62.1%) of sporadic CJD. Of these, 1340 cases were positive
(88.1%) (Table 1). Although the frequency of a positive
CSF 14-3-3 immunoassay was high for all three codon
129 genotypes, heterozygotes had a significantly lower rate
(77.0%) in adjusted analyses than VV (P < 0.001) and MM
(P < 0.05) (Table 2). Age at disease onset did not influence
CSF 14-3-3 protein detection but as for the EEG a positive
result was less likely with longer disease duration (Table 3)
(P < 0.001).
MR brain imaging was performed on 1063 patients
(42.3%). Of these patients, 405 patients showed character-
istic changes (39.1%) (Table 1). In contrast with the EEG, the
likelihood of a positive MRI scan was higher in cases with the
MV (P < 0.05) and VV genotypes (P = 0.002) in comparison
to those with an MM genotype (Table 2). MRI results were
not significantly associated with age at onset or disease
duration (Table 3).
Table 1 Summary of clinical features of all patients, including the subset undergoing molecular sub-typing
Clinical feature All patients Patients with molecular
sub-typing
Male (%) 1122 (45.8) 351 (47.2)
Female (%) 1329 (54.2) 392 (52.8)
Median age at onset (range) 67.2 (15.6–94.9) 66.2 (15.6–90.0)
Age at onset < 50 years (%) 116 (5.1) 39 (5.5)
Age at onset 50–59 years (%) 412 (18.2) 141 (19.7)
Age at onset 60–69 years (%) 867 (38.3) 286 (40.0)
Age at onset 70–79 years (%) 729 (32.2) 212 (29.7)
Age at onset > 80 years (%) 137 (6.1) 37 (5.2)
Median duration of illness in months (range) 5 (1–81) 5 (1–62)
Patients with duration < 6 months (%) 1332 (58.8) 404 (56.5)
Patients with duration 6–12 months (%) 611 (27.0) 179 (25.0)
Patients with duration > 12 months (%) 321 (14.2) 132 (18.5)
Codon 129 genotype
Met-Met/total (%) 1061/1604 (66.1) 504/743 (67.8)
Met-Val/total (%) 272/1604 (17.0) 117/743 (15.7)
Val-Val/total (%) 271/1604 (16.9) 122/743 (16.4)
Patients with PRNP gene sequenced (%) 1492 (63.6) 650 (87.5)
PrP isotype
Type 1 495/743 (66.6) 495/743 (66.6)
Type 1 and 2 44/743 (5.9) 44/743 (5.9)
Type 2 204/743 (27.5) 204/743 (27.5)
EEG
Typical/total (%) 1216/2083 (58.4) 371/666 (55.7)
14-3-3 protein in CSF
Positive/total (%) 1340/1521 (88.1) 486/554 (87.7)
MRI
Characteristic findings/total (%) 405/1036 (39.1) 150/387 (38.8)
Table 2 Summary of principal investigation findings for
all patients who underwent PRNP codon 129 genotyping
EEG MRI 14-3-3 protein
in CSF
Typical/total
(%)
Typical/total
(%)
Positive/total (%)
PRNP genotype
M/M 710/970 (73.2) 172/474 (36.3) 709/796 (89.1)
M/V 99/245 (40.4) 65/134 (48.5) 147/191 (77.0)
V/V 50/233 (21.5) 71/139 (51.1) 184/196 (93.9)
P-value <0.001 0.004 0.002
Adjusted by age at onset, disease duration, sex, country of origin
and year of death.
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Analysis of sporadic CJD patients
according to molecular sub-type
In 743 patients the codon 129 polymorphism and brain
PrPres isotype were determined allowing molecular
phenotypic sub-stratification (Table 1) (Parchi et al.,
1999). In 87% of these patients the PRNP gene was
sequenced, ruling out pathological mutations associated
with genetic CJD. In comparison to the entire group, the
median age at onset, median disease duration and PRNP
codon 129 polymorphism distributions were similar, and
there were no significant differences in the overall rates
of positive results for each of the investigations. The most
common PrPres isotype was type 1 (67%); type 2 was present
in 27% of the sample, and in 44 cases (6%) there was coex-
istence of both type 1 and 2.
The relative frequency of the various molecular sub-types
is provided in Table 4. There were occasional significant
differences in demographic characteristics between sub-
groups. MM1 patients were the oldest at disease onset (med-
ian: 67.8 years) and VV1 patients were the youngest (median:
47.2 years). The duration of the disease was significantly
shorter in MM1 patients (median: 4 months) in comparison
with the rest, especially the MM2 (median: 12.5 months) and
MV2 (median: 12 months) subgroups, with these groups also
Table 3 Principal investigation findings for all patients according to age at disease onset and duration of illness
EEG MRI 14-3-3 protein in CSF
Typical/total (%) Typical/total (%) Positive/total (%)
Age at onset
Age at onset < 50 years (%) 35/104 (33.7) 18/58 (31.0) 62/77 (80.5)
Age at onset 50–59 years (%) 197/371 (53.1) 83/196 (42.3) 222/260 (85.4)
Age at onset 60–69 years (%) 457/796 (57.4) 166/415 (40.0) 472/545 (86.6)
Age at onset 70–79 years (%) 438/675 (64.9) 126/328 (38.4) 452/492 (91.9)
Age at onset > 80 years (%) 81/124 (65.3) 12/37 (32.4) 73/83 (88.0)
P for trend <0.001 0.3 0.4
Disease duration
Patients with duration < 6 months (%) 814/1228 (66.3) 203/587 (34.6) 779/840 (92.7)
Patients with duration 6–12 months (%) 283/558 (50.7) 125/287 (43.6) 358/408 (87.7)
Patients with duration > 12 months (%) 115/288 (39.9) 77/160 (48.1) 146/211 (69.2)
P for trend 0.001 0.4 <0.001
Adjusted by PRNP codon 129 genotype, sex, country of origin and year of death.
Table 4 Summary of age at disease onset and illness duration for all patients undergoing molecular sub-typing
Sporadic CJD molecular sub-types
MM1 MM2 MM1/2 MV1 MV2 MV1/2 VV1 VV2 VV1/2
Total number (%) 444 (59.8) 31 (4.2) 29 (3.9) 37 (5.0) 73 (9.8) 7 (0.9) 14 (1.9) 100 (13.5) 8 (1.1)
Median age
at onset (range)
67.8
(31.1–89.4)
60.3
(37.7–82.3)*
65.6
(48.9–89.9)
65.5
(15.6–84.2)
63.6
(40.8–81.1)*
66.3
(56.7–77.9)
47.2
(23.6–72.7)*
66.3
(40.2–86.3)
59.7
(18.7–72.7)
Age at onset
< 50 years (%)
12 (2.8) 5 (16.7)† 1 (3.8) 1 (2.8) 2 (2.9) 0 (0.0) 7 (53.8)† 9 (9.3)† 2 (25.0)†
Age at onset
50–59 years (%)
78 (18.2) 9 (30.0) 3 (11.5) 9 (25.0) 17 (24.6) 1 (14.3) 2 (15.4) 20 (20.6) 2 (25.0)
Age at onset
60–69 years (%)
172 (40.1) 11 (36.7) 12 (46.2) 10 (27.8) 37 (53.6)† 3 (42.9) 3 (23.1) 35 (36.1) 3 (37.5)
Age at onset
70–79 years (%)
143 (33.3) 4 (13.3)* 7 (26.9) 13 (36.1) 12 (17.4)* 3 (42.9) 1 (7.7) 28 (28.9) 1 (12.5)
Age at onset
> 80 years (%)
24 (5.6) 1 (3.3) 3 (11.5) 3 (8.3) 1 (1.4) 0 (0.0) 0 (0.0) 5 (5.2) 0 (0.0)
Median duration
(months) (range)
4.0
(1.0–39.0)
12.5
(3.0–38.0)†
6.0
(2.0–33.0)
5.0
(1.0–54.0)†
12.0
(3.0–62.0)†
13.0
(2.0–30.0)
11.0
(2.0–29.0)†
6.0
(2.0–25.0)†
5.5
(3.0–62.0)
Duration
< 6 months (%)
307 (71.6) 9 (30.0)* 11 (42.3)* 21 (58.3) 5 (7.2)* 3 (42.9) 4 (30.8)* 40 (41.2)* 4 (50.0)
Duration 6–12
months (%)
78 (18.2) 4 (13.3) 11 (42.3)† 7 (19.4) 28 (40.6)† 0 (0.0) 3 (23.0) 47 (48.5)† 1 (12.5)
Duration
> 12 months (%)
44 (10.3) 17 (56.7)† 4 (15.4) 8 (22.2)† 36 (52.2)† 4 (57.1)† 6 (46.2)† 10 (10.3) 3 (37.5)†
Female (%) 239 (53.8) 15 (48.4) 14 (48.3) 18 (48.6) 35 (47.9) 5 (71.4) 5 (35.7) 56 (56.0) 5 (62.5)
*Significantly lower than MM1 (P < 0.05); †Significantly higher than MM1 (P < 0.05).
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demonstrating a higher percentage of patients with disease
lasting >1 year (57 and 52%, respectively). Of note, albeit the
small patient numbers preclude statistically significant dif-
ferences, patients with co-existence of PrPres types 1 and 2
(MM1/2, VV1/2 and MV1/2) tended to have intermediate
phenotypes but generally aligning more to the most common
molecular PrPres sub-type within each PRNP codon 129
genotype.
Overall, determinants of investigation findings in patients
who underwent molecular sub-typing were the same as for
the entire group. Independent of disease duration and mole-
cular sub-type, age at disease onset correlated significantly
with a positive EEG result (P = 0.007) (Fig. 1). Patients who
developed symptoms <50 years had a lower rate of typical
PSWCs (22%) than patients presenting after 60 years of age.
The median age at onset of the patients with an atypical EEG
was 64 years (range: 16–86), compared with 68 years (range:
31–90) in patients showing the typical findings. CSF 14-3-3
protein immunoassay and MRI results were not significantly
correlated with patient’s age at disease onset.
The duration of disease was independently associated
with the likelihood of PSWCs. Patients with disease duration
<6 months had a significantly higher rate (P = 0.02) of a
typical EEG than patients with duration >12 months (65
versus 35%, respectively). The median disease duration of
patients with an atypical EEG was 6 (range: from 1 to 62)
versus 4 months (range: from 1 to 39) in patients with typical
EEG. Disease duration significantly (P = 0.004) influenced
the likelihood of a positive CSF 14-3-3 test result. Those
patients with disease duration <6 months had a higher
rate of positive test results than those with duration >12
months (91 versus 72%, respectively). On average, patients
with 14-3-3 proteins detectable in their CSF had shorter
disease durations (median: 5 months, range: 1–39) than
patients with a negative test result (median: 11 months,
range: 2–54). MRI results did not correlate with disease
duration (Fig. 2).
Certain molecular sub-types showed significant correla-
tions with investigation results. MM1 patients demonstrated
the highest frequency of positive EEG results (73%) followed
by MV1 patients (53%), although after adjusting for covari-
ates the significance was reduced (P = 0.01). VV2 and MV2
patients had infrequent occurrence of a typical EEG, with a
positive result only observed in 12.8 and 17.5% of the cases,
respectively (Fig. 3). Of the sub-groups with coexistence of
PrPres types, only VV1/2 patients had a significantly lower
frequency compared with the MM1 subgroup. CSF 14-3-3
immunoassay was the most frequently positive investigation,
with an overall positive rate of 88%. However, there were
some significant variations across molecular sub-types, with
the test significantly more often positive (all P-values < 0.05)
for MM1 and VV2 patients (91 and 95%) than for MM2
(61%) and MV2 (71%) (Fig. 3). Of the patient groups with
coexistence of PrPres types, only MM homozygotes had a
significantly lower rate of positive results for this test
(Fig. 3). For MRI, only the VV2 subgroup demonstrated a
significantly increased likelihood of a typical positive result.
Of note, within each molecular sub-type except VV1, occa-
sional patients did not display typical or characteristic find-
ings with any of the three investigations.
Assessment of the influence of the time
point of the investigation during a patient’s
illness on the test result
For both EEG and the detection of CSF 14-3-3 proteins,
sufficient data were available to analyse the influence of
the time point at which the investigation was performed
Fig. 1 The principal investigation results for EEG, brain MRI and CSF 14-3-3 protein analysis were correlated with age at disease onset in
sporadic CJD for all patients undergoing molecular sub-typing. Patients were grouped by age at onset: <50, 50–59, 60–69, 70–79 and
>80 years. Only the EEG showed a significant correlation with age at disease onset. †Significantly higher than in <50 years group (P < 0.05);
adjusted by molecular sub-type, disease duration, sex, country of origin, year of death.
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Fig. 2 The principal investigation results for EEG, brain MRI and CSF 14-3-3 protein analysis were correlated with disease duration
in sporadic CJD for all patients undergoing molecular sub-typing. Disease duration was arranged as <6, 6–12 and >12 months.
For both the EEG and CSF 14-3-3 protein detection there was a significant inverse correlation with disease duration >12 months.
* Significantly lower than in <12-months group (P < 0.05); adjusted by molecular sub-type, age at onset, sex, country of origin,
year of death.
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Fig. 3 The sensitivities of EEG, brain MRI and CSF 14-3-3 protein detection were assessed according to the sporadic CJD molecular
sub-type: MM1, MM2, MM1/2; MV1, MV2, MV1/2; and VV1, VV2 and VV1/2. The MV1, MV2, VV2 and VV1/2 sub-types all showed a
significantly reduced EEG sensitivity, while the VV2 sub-type displayed a significantly higher likelihood of a typical MRI result.
The MM2, MM1/2 and MV2 sub-types all showed significantly reduced rates of CSF 14-3-3 protein positivity. * Significantly lower than MMI
(P < 0.05); †significantly higher than MMI (P < 0.05); adjusted by age at onset, disease duration, sex, country of origin, year of death.
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during the patient’s illness on the likelihood of a typical or
positive result. With the median duration of illness only 5
months, we chose to divide the symptomatic phase into
thirds (first, middle and final) rather than into a greater
number of epochs. This was undertaken to avoid the creation
of illness phases of such brevity, especially at the onset of
symptoms, that they would be unlikely to correspond to a
clinically meaningful period of a patient’s illness during
which investigations would usually be undertaken and
that the test would have a reasonable chance of showing
typical abnormalities.
With respect to EEGs, 2425 recordings with a known time
point in relation to the chronology of the patient’s illness
were available for analysis from 1728 cases. When analysed in
isolation, the likelihood of a typical EEG was significantly less
in the first third of a patient’s illness compared with the last
third (P = 0.02). Multivariate analysis (adjusted by country,
gender, year of death, age at onset, disease duration and
codon 129 polymorphism) also showed that a positive
EEG was significantly more likely in the last third of a
patient’s illness compared with the first third (P = 0.001).
When a patient’s molecular sub-type was substituted for
codon 129 polymorphism in the same regression model,
however, a typical periodic EEG was no longer significantly
more likely in any particular time period of the patient’s
illness. These results are consistent with the specific time
point at which the diagnostic test is undertaken during
the symptomatic period of a patient’s illness not being
independent of molecular sub-type in determining the
likelihood of a positive EEG. With respect to detection of
CSF 14-3-3 proteins, 1032 assays from 985 cases were avail-
able for analysis, showing no significant association between
a positive result and the time point of sampling during a
patient’s illness, regardless of whether assessed in isolation or
in analogous multivariate analyses. For each of the first,
middle and final third time periods of patient’s illnesses,
the CSF 14-3-3 protein sensitivities were 88, 86.4 and
91.3%, respectively.
Discussion
The current study is by far the largest to date to assess the
diagnostic sensitivity of investigations usually employed in
the evaluation of suspected sporadic CJD. By virtue of the
large number of definite sporadic CJD patients comprising
our study we have been able to confidently delineate the
sensitivities of the principal investigation results across the
entire phenotypic spectrum, especially the less common
molecular sub-types, as well as clarify and extend hitherto
uncertain independent determinants of investigation results
(Pocchiari et al., 2004). Analysis of only neuropathologically
confirmed CJD patients has allowed us to avoid the inherent
difficulties that arise from analysis of investigations that also
serve in case definition criteria for probable cases; however, it
is noteworthy that separate analysis of all EUROCJD spora-
dic CJD patients from this time period, that is, inclusion of
clinically probable cases, gave the same results as analysis of
just definite cases (data not shown). Multivariate regression
modelling demonstrated that age at disease onset and disease
duration both act as independent determinants of some
investigation results in sporadic CJD, in addition to the
influence of molecular sub-type. Consequently, in the clinical
evaluation of suspect CJD, our findings reinforce the impor-
tance of fully appreciating the limitations of specific inves-
tigations relative to these salient patient clinical features;
otherwise the heightened likelihood of a negative test result
may be underestimated and incorrectly interpreted as undue
reassurance against the diagnosis. Specifically, the probability
that an EEG will demonstrate PSWCs increases with age and
conversely decreases with disease duration, especially if >12
months. Hence, in a patient <50 years it is most likely that an
EEG will not show typical changes, and even in older
patients, if their illness is >6 months, the probability of
PSWCs is at best only 50%. In contrast to a prior smaller
study (Zerr et al., 2000b) disease duration >12 months was
also observed to significantly lessen the likelihood of a posi-
tive CSF 14-3-3 result. This underscores the importance of
acknowledging illness duration when interpreting a negative
result in an individual patient suspected to be manifesting
sporadic CJD.
The present study re-affirmed that molecular sub-type, in
addition to age at onset and illness duration, is also an
important independent determinant of principal investiga-
tion results (Parchi et al., 1999; Zerr et al., 2000b; Otto et al.,
2002; Hill et al., 2003; Castellani et al., 2004; Meissner et al.,
2004). In contrast to the EEG, where the presence of valine
alleles at codon 129 additively reduces the likelihood of
PSWCs, valine homozygotes (especially VV2 patients)
were significantly more likely to demonstrate a typical
MRI scan than methionine homozygotes (particularly the
MM1 subgroup). These data conform to a pattern whereby
sub-types with ‘classical’ sporadic CJD and predominant
cerebral cortical involvement (MM1 and MV1) are more
likely to manifest PSWCs on EEG, while those with ataxia
and subcortical neuropathological changes (VV2 and MV2)
are more likely to demonstrate characteristic basal ganglia
changes on MRI. However, in contrast to a prior report
suggesting phenotypic homogeneity between the MM1
and MV1 sub-types (Parchi et al., 1999), we found that
the likelihood of a typical EEG was significantly lower and
the average illness duration significantly longer in the MV1
patients. The most likely explanation for this difference in
findings is the much larger sample of MV1 patients available
for analysis in our study.
The CSF 14-3-3 protein immunoassay was the most sen-
sitive investigation across the sporadic CJD phenotypic spec-
trum, but the influence of molecular sub-type was still
evident. Codon 129 heterozygotes, especially the MV2
sub-group, were significantly less likely to be associated
with a positive result [Zerr et al., 2000a, b; Otto et al.,
2002; Castellani et al., 2004], as were the very uncommon
MM2 and MM1/2 subgroups. In comparison with the simple
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demographic features of age at disease onset and illness
duration, the molecular sub-typing profile is much less likely
to be available pre-mortem in individual patients. Neverthe-
less, if this information is available, investigation results
would also need to be interpreted in this specific context
for the most accurate estimation of excluding or confirming
the likelihood of sporadic CJD. Having recognized these
overall limitations and variations across the molecular
sub-types, from a practical clinical perspective it would
appear prudent to utilize all three principal investigations
(brain MRI, CSF 14-3-3 protein analysis and EEG), as, irre-
spective of molecular sub-type, only very uncommonly
(except the rare MM2 sub-group) will all three investigations
not show characteristic findings in an individual patient with
sporadic CJD (Shiga et al., 2004).
Our analyses do not suggest that the time point at which
the investigation is undertaken during a patient’s illness is an
independent determinant of the test result. This was parti-
cularly evident for CSF 14-3-3 protein detection, for which
no association between time point of sampling and a positive
result was found regardless of analytical approach. For EEG,
the apparent reduced likelihood of a typical or periodic
recording in the first third of a patient’s illness compared
with the final period, when examined in isolation or with one
of the multivariate regression models, was no longer evident
when the regression model included molecular sub-type.
Collectively, our findings are consistent with the generally
dominant influence of age at onset, illness duration and
molecular sub-type as the key independent determinants
of investigation results compared with other demographic
variables, including the time point of test sampling during a
patient’s illness.
Although molecular sub-typing of sporadic CJD patients
has proven a useful phenotypic classification system, there
are some difficulties with this approach. Not uncommonly,
more than one PrPres type may be present in the brain of a
patient dying from sporadic CJD (Parchi et al., 1999), and it
is likely that the frequency of occurrence increases with the
number of regions assessed (Puoti et al., 1999; Head et al.,
2004). At present, there is no consensus on how to classify
such patients and whether it is generally better to adopt a
dichotomized approach based on predominance of one type
when several regions are studied or accept classification
based on the analysis of only one or two brain sites. In
our study, patients with more than one PrPres type were a
small minority, but such patients were allowed status as a
separate group within each PRNP genotype without attempt-
ing to adjust for relative abundance of the two PrPres types.
Regardless of PRNP genotype, our patients with simulta-
neous occurrence of both PrPres types tended to present a
different phenotype, sometimes intermediate between those
with a single PrPres isotype and the same codon 129 status,
but often extending beyond the range observed. This suggests
that the simultaneous presence of two PrPres types may evoke
a third or unique phenotype within each codon 129 geno-
type, although our small patient numbers militated against
achieving significance with these observations. Analysis of
investigation results also generally suggests that subgroups
with co-existence of PrPres isotypes tended to appear differ-
ent although not invariably. For CSF 14-3-3 results, the
MM1/2 group behaved more like MM2 patients, and for
the EEG the VV1/2 group were also more like the VV2
patients. The latter is in keeping with the predominant phe-
notypic influence of type 2 PrPres on these investigations or
may simply represent a sampling bias wherein type 2 PrPres
was under-appreciated as the dominant protease resistant
isotype across the brain.
MRI brain imaging is now very commonly employed in
the diagnostic evaluation of suspected sporadic CJD but its
ultimate sensitivity and specificity is still being defined
(Finkenstaedt et al., 1996; Collie et al., 2001; Meissner
et al., 2004; Shiga et al., 2004; Tschampa et al., 2005). For
a number of reasons, our overall sensitivity for typical
changes on MRI scan is lower than that reported in much
smaller studies (Finkenstaedt et al., 1996; Schro¨ter et al.,
2000; Zerr et al., 2000b; Meissner et al., 2004; Shiga et al.,
2004; Tschampa et al., 2005). Importantly, patient MRI
data collected for this study extended over a decade, during
which time this imaging technique was increasingly used
in the evaluation of suspect sporadic CJD, and there were
concurrent improvements in the diagnostic sensitivity of
pulse sequences used for this illness (Collie et al., 2001;
Shiga et al., 2004; Tschampa et al., 2005). Consequently,
the overall number of patients studied with MRI was rela-
tively low (42.3%), and the utilization of optimized MRI
techniques such as DWI and FLAIR mainly occurred only
in the very latter phase of our study epoch and even then was
not uniformly adopted by all neuroimaging services. Further,
during the study period there was progressive appreciation
that increased cerebral cortical signal using the more sensi-
tive techniques of DWI and FLAIR is probably a reasonably
common feature in sporadic CJD (Shiga et al., 2004;
Tschampa et al., 2005). Consequently, another reason for
our low MRI sensitivity relates to our restrictive definition
of what changes we considered characteristic of the diagnosis
(i.e. signal hyperintensity limited to the basal ganglia). Over-
all, this combination of factors has compromised our assess-
ment of the true diagnostic sensitivity and clinical utility of
MRI in the evaluation of sporadic CJD. This sub-optimal
aspect of the present study is being redressed by a further
prospective EUROCJD collaborative project.
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